Research programme: asthma VPAC2 receptor agonists - Forbes Medi-Tech
Alternative Names: FM-TP3000Latest Information Update: 27 May 2008
At a glance
- Originator Forbes Medi-Tech
- Class
- Mechanism of Action Vasoactive intestinal peptide type II receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Asthma; Chronic obstructive pulmonary disease; Pulmonary arterial hypertension
Most Recent Events
- 27 May 2008 Discontinued - Preclinical for Asthma in Canada (unspecified route)
- 27 May 2008 Discontinued - Preclinical for Chronic obstructive pulmonary disease in Canada (unspecified route)
- 27 May 2008 Discontinued - Preclinical for Pulmonary hypertension in Canada (unspecified route)